Candel Therapeutics highlights third quarter milestones across cancer immunotherapy pipelineProactive Investors • 11/13/25
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/13/25
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid TumorsGlobeNewsWire • 11/04/25
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in LondonGlobeNewsWire • 11/03/25
Candel Therapeutics strengthens Research Advisory Board with appointment of immunology expertProactive Investors • 10/16/25
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory BoardGlobeNewsWire • 10/16/25
Candel Therapeutics secures $130M loan to advance cancer therapy trialsProactive Investors • 10/14/25
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.GlobeNewsWire • 10/14/25
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight CancerPRNewsWire • 10/14/25
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational MedicineGlobeNewsWire • 10/14/25
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025GlobeNewsWire • 09/29/25
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025GlobeNewsWire • 09/17/25
Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough TumorsSeeking Alpha • 09/05/25
Candel Therapeutics adds immunotherapy expert to Research Advisory BoardProactive Investors • 09/02/25
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.GlobeNewsWire • 09/02/25
Candel Therapeutics to Participate in Upcoming Investor Conferences in SeptemberGlobeNewsWire • 08/28/25